KALA BIO, INC. Acquisitions, Net of Cash Acquired
KALA BIO, INC. (KALA) reported Acquisitions, Net of Cash Acquired of $4.65 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2023-03-03
- KALA BIO, INC. payments to acquire businesses, net of cash acquired for fiscal 2021 was $4.65M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|
| 2021-12-31 | $4.65M 10-K · filed 2023-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |